Panel Discussion: How do we Differentiate Degraders from Inhibitors as a Therapeutic Modality?
Time: 10:00 am
day: Conference Day Two
Details:
- How do we break away from the inhibitor-based ligands like BRAF? Do we need to?
- How are we finding new, exciting targets?
- How do we address the problems with VHL pharmacology such as its larger size?
